Cargando…
Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report
Epithelial ovarian cancer is extremely difficult to treat due to its high recurrence rate and acquired tolerance to chemotherapy. Immune checkpoint inhibitors (ICIs) are expected to be promising solutions for treatment failure. However, the low response rate to a single ICI agent was demonstrated in...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670358/ https://www.ncbi.nlm.nih.gov/pubmed/34338238 http://dx.doi.org/10.1097/CAD.0000000000001178 |
_version_ | 1784614963998883840 |
---|---|
author | Sun, Shaoxing Sun, Wenjie Xiang, Qingming Yang, Chunxu Chen, Min Mei, Zijie Yang, Hui Zeng, Zihang Cao, Hong Tian, Yueli Zhang, Gong Qiu, Hui |
author_facet | Sun, Shaoxing Sun, Wenjie Xiang, Qingming Yang, Chunxu Chen, Min Mei, Zijie Yang, Hui Zeng, Zihang Cao, Hong Tian, Yueli Zhang, Gong Qiu, Hui |
author_sort | Sun, Shaoxing |
collection | PubMed |
description | Epithelial ovarian cancer is extremely difficult to treat due to its high recurrence rate and acquired tolerance to chemotherapy. Immune checkpoint inhibitors (ICIs) are expected to be promising solutions for treatment failure. However, the low response rate to a single ICI agent was demonstrated in approximately all published clinical trials. Surprisingly patients with complete response were also noticed as an anecdote. Proper indicators of treatment response were urgently required. Programmed death- ligand 1 expression levels in the tumor tissues provide relatively limited discrimination. Tumor mutation burden (TMB) serves as a more reliable parameter. Here we presented an ovarian cancer case with multiple gene mutations and high TMB, who benefited from a short-term treatment of pembrolizumab and experienced a long-lasting complete response of 2 years till now. The patient was irradiated in the pelvic before pembrolizumab. Our study demonstrated that ICIs might provide survival benefits for ovarian cancer with high TMB and that pelvic radiation might have synergistical effects with immunotherapy. |
format | Online Article Text |
id | pubmed-8670358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-86703582021-12-15 Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report Sun, Shaoxing Sun, Wenjie Xiang, Qingming Yang, Chunxu Chen, Min Mei, Zijie Yang, Hui Zeng, Zihang Cao, Hong Tian, Yueli Zhang, Gong Qiu, Hui Anticancer Drugs Case Reports Epithelial ovarian cancer is extremely difficult to treat due to its high recurrence rate and acquired tolerance to chemotherapy. Immune checkpoint inhibitors (ICIs) are expected to be promising solutions for treatment failure. However, the low response rate to a single ICI agent was demonstrated in approximately all published clinical trials. Surprisingly patients with complete response were also noticed as an anecdote. Proper indicators of treatment response were urgently required. Programmed death- ligand 1 expression levels in the tumor tissues provide relatively limited discrimination. Tumor mutation burden (TMB) serves as a more reliable parameter. Here we presented an ovarian cancer case with multiple gene mutations and high TMB, who benefited from a short-term treatment of pembrolizumab and experienced a long-lasting complete response of 2 years till now. The patient was irradiated in the pelvic before pembrolizumab. Our study demonstrated that ICIs might provide survival benefits for ovarian cancer with high TMB and that pelvic radiation might have synergistical effects with immunotherapy. Lippincott Williams & Wilkins 2021-07-30 2022-01 /pmc/articles/PMC8670358/ /pubmed/34338238 http://dx.doi.org/10.1097/CAD.0000000000001178 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Case Reports Sun, Shaoxing Sun, Wenjie Xiang, Qingming Yang, Chunxu Chen, Min Mei, Zijie Yang, Hui Zeng, Zihang Cao, Hong Tian, Yueli Zhang, Gong Qiu, Hui Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report |
title | Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report |
title_full | Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report |
title_fullStr | Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report |
title_full_unstemmed | Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report |
title_short | Persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report |
title_sort | persistent response of an ovarian cancer patient after a short-term single-agent immunotherapy: a case report |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670358/ https://www.ncbi.nlm.nih.gov/pubmed/34338238 http://dx.doi.org/10.1097/CAD.0000000000001178 |
work_keys_str_mv | AT sunshaoxing persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport AT sunwenjie persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport AT xiangqingming persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport AT yangchunxu persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport AT chenmin persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport AT meizijie persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport AT yanghui persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport AT zengzihang persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport AT caohong persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport AT tianyueli persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport AT zhanggong persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport AT qiuhui persistentresponseofanovariancancerpatientafterashorttermsingleagentimmunotherapyacasereport |